Libtayo® (cemiplimab-rwlc)

news

EC approves Libtayo^® for metastatic cervical cancer

24 November 2022 | By Catherine Eckford (European Pharmaceutical Review)

The European Commission has approved Libtayo® for cervical cancer and disease progression while on or after platinum-based chemotherapy, due to positive Phase III trial results.

news

FDA approves Libtayo^® monotherapy for non-small cell lung cancer patients

23 February 2021 | By Hannah Balfour (European Pharmaceutical Review)

The approval was based on a Phase III trial in which Libtayo reduced risk of death by 43 percent in non-small cell lung cancer patients with ≥50 percent PD-L1 expression in their tumours.

news

First immunotherapy for advanced basal cell carcinoma approved in US

11 February 2021 | By Hannah Balfour (European Pharmaceutical Review)

In trials Libtayo® caused clinically meaningful and durable responses, resulting in the drug being fully approved for advanced basal cell carcinoma resistant to other treatments.